Here is what I found from the Mayo Clinic.......
A randomized controlled crossover trial of aspirin for fatigue in multiple sclerosis
D. M. Wingerchuk, MD, FRCPC, E. E. Benarroch, MD, P. C. O’Brien, PhD, B. M. Keegan, MD, FRCPC, C. F. Lucchinetti, MD, J. H. Noseworthy, MD, FRCPC, B. G. Weinshenker, MD, FRCPC and M. Rodriguez, MD
From the Department of Neurology Mayo Clinic, Scottsdale, AZ (Dr. Wingerchuk) and Rochester, MN (Drs. Benarroch, Keegan, Lucchinetti, Noseworthy, Weinshenker, and Rodriguez), and Department of Biostatistics (Dr. O’Brien), Mayo Clinic, Rochester, MN.
Pharmacotherapeutic options for multiple sclerosis (MS)-related fatigue are limited. Thirty patients were randomly assigned to aspirin (ASA) 1,300 mg/day or placebo in a double-blind crossover study. Results favored ASA for the main clinical outcomes: Modified Fatigue Impact Scale scores (p = 0.043) and treatment preference (p = 0.012). There were no significant adverse effects. The results warrant further study and support a role for ASA-influenced mechanisms, perhaps immunologic, in the generation of MS-related chronic fatigue.